Resources
31 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 2/9/2024 (updated 3/28/2024)
The U.S. Department of Health and Human Services, through its Office for Civil Rights (OCR) and the Substance Abuse and Mental Health Services Administration (SAMHSA), finalized modifications to the Confidentiality of Substance Use Disorder (SUD) Patient Records regulations at 42 CFR part 2 (“Part 2”), which protect the privacy of patients’ SUD treatment records.
Posted 1/26/2024 (updated 3/28/2024)
On January 18, 2024, the Centers for Medicare & Medicaid Services (CMS) announced the Innovation in Behavioral Health (IBH) Model. IBH is focused on improving quality of care and behavioral and physical health outcomes for Medicaid and Medicare populations with moderate to severe mental health conditions and substance use disorder (SUD).
Posted 12/1/2023 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) released results of the 2022 National Survey on Drug Use and Health (NSDUH). The NSDUH provides information on substance use and mental health rates in the United States with data on the self-reported use of tobacco, alcohol, and illicit drugs; substance use disorders; mental health conditions; and suicidal thoughts and behaviors. SAMSHA also released a high-level brief of the report with infographics.
Posted 11/17/2023 (updated 3/28/2024)
Celebrate and honor the culture, traditions, and achievements of the nation's original inhabitants and of their descendants. The U.S Department of Health and Human Services (HHS) and the HHS Office of Minority Health (OMH) honor the history, culture, and legacy of Tribal nations and Indigenous communities across the United States.
Posted 10/27/2023 (updated 3/28/2024)
As announced by the Substance Abuse and Mental Health Services Administration in January 2023, clinicians no longer need a federal waiver to prescribe buprenorphine for treatment of opioid use disorder. Clinicians will still be required to register with the federal Drug Enforcement Agency (DEA) to prescribe controlled medications. On June 27, the DEA began to require that registration applicants – both new and renewing – affirm they have completed a new, one-time, eight-hour training.
Posted 12/20/2022 (updated 3/27/2024)
The Centers for Medicare & Medicaid Services (CMS) recently released the Calendar Year (CY) 2023 Physician Fee Schedule. This rule makes policy updates which may increase accessibility of behavioral health services and telehealth services in rural areas. CMS subject matter experts from the Hospital and Ambulatory Policy Group (HAPG) presented on the behavioral health and telehealth updates in the rule during the webinar held on Wednesday, December 14, 2022.
Posted 12/13/2022 (updated 3/27/2024)
The U.S. Department of Health and Human Services (HHS) announced the progress made since the release of the Overdose Prevention Strategy (Strategy) last fall. The new data shows treatment capacity, lives saved from overdose, and commitments to long-term recovery supports, as well as a hopeful trend of a decrease in overdose deaths.
Posted 12/6/2022 (updated 3/27/2024)
This week, the U.S. Health and Human Services Department, through the Office for Civil Rights (OCR) and the Substance Abuse and Mental Health Services Administration (SAMHSA), announced proposed changes to the Confidentiality of Substance Use Disorder (SUD) Patient Records under 42 CFR part 2 (“Part 2”), which protects patient privacy and records concerning treatment related to substance use challenges from unauthorized disclosures.
Posted 4/14/2023 (updated 3/27/2024)
The next National Prescription Drug Take Back Day is on April 22, 2023. If you have unused or expired prescription medications, you can locate a safe and convenient disposal drop off location using the U.S Drug Enforcement Association's (DEA) website. The DEA aims to help the public remove unneeded medications from their homes as a measure of preventing medication misuse and opioid addiction from ever starting.
Posted 3/14/2023 (updated 3/27/2024)
The Drug Enforcement Administration (DEA) announced proposed rules for the prescribing of controlled medications via telemedicine beyond the end of the COVID-19 public health emergency. One rule addresses the expansion of induction of buprenorphine via telemedicine encounter while the other covers telemedicine prescribing of controlled substances when the practitioner and the patient have not had a prior in-person medical evaluation. While opioid use disorders occur at similar rates in both rural and urban areas, medication assisted treatment (MAT) prescribers have been disproportionately located in urban areas. The public will be able to comment on the proposed rules until March 31st.